FDA Approves Tryngolza for Familial Chylomicronemia Syndrome

443 Views

Emedinexus 23 December 2024

The FDA has approved Tryngolza (olezarsen), a groundbreaking drug for reducing triglycerides (TG) in adults with familial chylomicronemia syndrome (FCS). Taken alongside dietary management, this first-in-class therapy introduces a novel mechanism of action, setting it apart from existing FCS treatments.

To comment on this article,
create a free account.

Already registered?

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.